Detailed price information for Springworks Therapeutics Inc (SWTX-Q) from The Globe and Mail including charting and trades.

SpringWorks Therapeutics Inc. (NASDAQ:SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases and cancer.

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue ...

Merck KGaA expands rare tumor portfolio: The $3.4 billion acquisition of SpringWorks Therapeutics adds two FDA-approved therapies: Ogsiveo for desmoid tumors and Gomekli for neurofibromatosis type 1 ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nirogacestat, an oral gamma secretase ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.